MediWound Ltd. (MDWD) Receives “Buy” Rating from Oppenheimer Holdings, Inc.

Oppenheimer Holdings, Inc. restated their buy rating on shares of MediWound Ltd. (NASDAQ:MDWD) in a report published on Monday morning. The firm currently has a $10.00 target price on the biopharmaceutical company’s stock. Oppenheimer Holdings also issued estimates for MediWound’s Q3 2018 earnings at ($0.12) EPS.

Several other brokerages have also issued reports on MDWD. Aegis restated a buy rating and issued a $11.00 price objective on shares of MediWound in a report on Thursday, May 25th. Zacks Investment Research lowered shares of MediWound from a hold rating to a sell rating in a report on Tuesday, August 8th. Jefferies Group LLC set a $10.00 price objective on shares of MediWound and gave the company a buy rating in a report on Friday, August 25th. Finally, SunTrust Banks, Inc. restated a buy rating on shares of MediWound in a report on Monday, June 26th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. MediWound presently has a consensus rating of Buy and an average target price of $9.19.

MediWound (NASDAQ:MDWD) opened at 6.05 on Monday. MediWound has a 12-month low of $4.25 and a 12-month high of $8.58. The stock has a 50 day moving average of $6.35 and a 200-day moving average of $6.54. The company’s market capitalization is $132.82 million.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The company had revenue of $0.69 million during the quarter, compared to analysts’ expectations of $0.69 million. MediWound had a negative net margin of 752.78% and a negative return on equity of 326.32%. The firm’s quarterly revenue was up 93.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.34) earnings per share. Equities analysts expect that MediWound will post ($0.77) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “MediWound Ltd. (MDWD) Receives “Buy” Rating from Oppenheimer Holdings, Inc.” was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2017/09/19/mediwound-ltd-mdwd-receives-buy-rating-from-oppenheimer-holdings-inc.html.

Large investors have recently modified their holdings of the business. Wells Fargo & Company MN increased its stake in MediWound by 19.7% during the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock worth $351,000 after purchasing an additional 8,745 shares during the period. Renaissance Technologies LLC increased its stake in MediWound by 1.7% during the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 1,300 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its stake in MediWound by 20.3% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock worth $13,791,000 after purchasing an additional 342,165 shares during the period. Finally, Wellington Management Group LLP increased its stake in MediWound by 11.0% during the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock worth $14,241,000 after purchasing an additional 213,745 shares during the period. Institutional investors own 23.47% of the company’s stock.

MediWound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply